Ahead of the Bell: King Pharmaceuticals - Forbes.com: "pic
NEW YORK -- Wall Street gave a positive nod to King Pharmaceuticals Inc. following Food and Drug Administration approval of the company's abuse-resistant painkiller Embeda.
The stock was recently unchanged from Thursday's close at $10.68., but had earlier jumped as much as 4.7 percent, to reach $11.08."
www.stockcaps.blogspot.com
 | Company Earnings Earnings Dates, Surprises, Conference Calls |  | Financial Calendars Stock Splits, Economic, IPOs, Mergers |
 | Analyst Research Report Screener, Analyst Performance Center, Up/Downgrades, Sector/Industry Analysis |  | Research Tools Stock Screener, Historical Quotes, Real-Time Quotes |
 | Company Reports Annual Reports, SEC Filings, Financial Statements |  | Bonds Bond Center, Bond Screener, Bond News, Bond Rates |
 | Mutual Funds Mutual Fund Center, Fund Screener, Top Performers |  | Options Options Center, Options News, Options 101 |
Friday, August 14, 2009
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment